InflaRx (NASDAQ:IFRX) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

InflaRx (NASDAQ:IFRX) released its quarterly earnings data on Tuesday. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.04, FiscalAI reports.

Here are the key takeaways from InflaRx’s conference call:

• InflaRx sees a $1.5 billion–$2 billion peak-sales opportunity for izicopan in ANCA-associated vasculitis, based on physician market research and potential use in the 70%–80% of patients with renal involvement.
• The company believes izicopan could offer faster onset, higher exposure, lower pill burden, and fewer drug–drug interaction concerns than avacopan; 197 subjects have been dosed to date without reported safety signals of concern, although longer-term data remain limited.
• InflaRx plans two parallel phase II AAV studies: a randomized, placebo-controlled renal vasculitis trial focused on eGFR, proteinuria, hematuria, and remission, and an open-label study designed to test rapid corticosteroid tapering and potential replacement.
• External experts emphasized that AAV remains a serious, frequently relapsing disease with substantial kidney damage, infection risk, and glucocorticoid toxicity, while prior avacopan data support steroid-sparing and renal-function benefits but remain clouded by a retracted publication and ongoing FDA availability questions.
• InflaRx reported EUR 153.3 million in cash and a runway through 2029, with additional programs planned in atypical hemolytic uremic syndrome, IgA nephropathy, and rapidly progressive IgA nephropathy; initial readouts are expected as early as 2027–2028.

InflaRx Trading Down 10.8%

IFRX stock traded down $0.19 during mid-day trading on Tuesday, hitting $1.57. 3,246,348 shares of the company were exchanged, compared to its average volume of 1,043,080. The firm has a fifty day simple moving average of $1.86 and a 200 day simple moving average of $1.63. The company has a market capitalization of $232.11 million, a PE ratio of -2.72 and a beta of 2.59. InflaRx has a twelve month low of $0.80 and a twelve month high of $2.95.

Wall Street Analyst Weigh In

IFRX has been the subject of a number of research reports. Zacks Research cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, September 21st. Cantor Fitzgerald lifted their price objective on shares of InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Needham & Company LLC began coverage on shares of InflaRx in a research report on Monday, September 14th. They set a “buy” rating and a $8.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, InflaRx has an average rating of “Moderate Buy” and a consensus price target of $7.43.

InflaRx Company Profile

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.